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TIEG1KLF10 is now classiﬁed as a member of the Krüppel-like transcription factor family and acts as a tumor suppres-
sor. Although KLF10 is originally named as TGF-β-inducible early gene-1 andmimicking the anti-proliferative ef-
fect of TGF-β in various carcinoma cells, the transcriptional upregulatory function of KLF10 has beendescribed for
a variety of cytokines and in many diseases. Through in vivo and in vitro phosphorylation assays, we identiﬁed
that KLF10 is a phosphorylated protein in cells. Using yeast-two hybrid screening and site direct mutagenesis,
we also identiﬁed PIN1 as a novel KLF10 associated protein. PIN1 is a peptidyl-prolyl isomerase enzyme belong-
ing to the parvulin family, which speciﬁcally recognizes phosphorylated Ser/Thr-Pro containing substrates.
Through protein–protein interaction assays, we showed that the Pro-directed Ser/Thr-Pro motif at Thr-93 in
the KLF10 N-terminal region is essential for the interaction between KLF10 and PIN1. More importantly, PIN1 in-
teracts with KLF10 in a phosphorylation-dependent manner and this interaction promotes KLF10 protein degra-
dation in cells. Therefore, KLF10 shows shorter protein stability compared with mutant KLF10 that lacks PIN1
binding ability after cycloheximide treatments. The reversely correlated expression proﬁle between KLF10 and
PIN1 as observed in cell lines was also shown in clinic pancreatic cancer specimen. Using in vitro kinase assays
and depletion assays, we were able to show that RAF-1 phosphorylates the Thr-93 of KLF10 and affects the
KLF10 expression level in cells. Thus these ﬁndings as a whole indicate that RAF-1 phosphorylation and PIN1
isomerization together regulate KLF10 stability and further affect the role of KLF10 in tumor progression.
© 2013 Published by Elsevier B.V.1. Introduction
KLF10 belongs to the Krüppel-like factor (KLF) family, which con-
sists of Cys2/His2 zinc ﬁnger proteins that play important roles in the
eukaryotic cellular transcriptional machinery. All KLF proteins share a
highly conserved C-terminal DNA-binding domain that is involved in
controlling a range of biological processes. However, their N-terminal
regions are highly variable and are involved in both gene regulation
and protein–protein interactions [1]. Based on previous studies, KLF
familymembers have been identiﬁed as key players in the transcription
networks that control cell proliferation, apoptosis, differentiation,
development and tumorigenesis [2,3]. The Klf10 gene, which was
originally named “TGF-β inducible early gene-1” (TIEG1), was ﬁrstnslation Medicine, College of
ty, 250 Wu-Hsing Street, Taipei
638 7537.
ancer Research, National Health
iaoli County 350, Taiwan. Tel.:
ng), winston@nhri.org.tw
vier B.V.identiﬁed in normal human fetal osteoblasts following TGF-β treatment
[4]. However, subsequent research focusing on KLF10 has demonstrated
that hormone and cytokines, including bone morphogenetic protein-2
(BMP-2), bone morphogenetic protein-4 (BMP-4), activin, nerve growth
factor, endothelin-1 and others are able to induce Klf10 expression [5,6].
Recently, KLF10 has been demonstrated to be involved in regulating a
range of different types of gene expression in various cell types. In
addition, it has been shown to be a target gene for various signaling path-
ways during cell differentiation. Finally, studies have indicated that it is a
potential marker for various human diseases including cancer, cardiac
hypertrophy and osteoporosis [6].
Expressions of humanKLF10 in cancer cells have been documented to
inhibit cell proliferation and induce apoptosis [6]. Moreover, the level of
KLF10 has been shown to be reversely associated with the progression
and stages of breast and pancreatic cancers [7,8]. The signiﬁcant correla-
tion of KLF10 with the presence of distant metastasis has revealed that
loss of KLF10 during pancreatic carcinogenesis may be responsible not
only for enhanced tumor cell proliferation and invasion but also for mi-
gration [7]. Although a great deal of research has suggested an important
role for KLF10 inmultiple biological processes and disease states, most of
these studies have focused on the transcriptional regulation of various
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SIAH1. In order to investigate what cellular proteins interact with
human KLF10, we used the yeast two-hybrid system and identiﬁed
peptidyl-prolyl cis–trans isomerase NIMA-interacting 1 (PIN1) as a
candidate protein for interaction with KLF10.
PIN1 is a peptidyl-prolyl cis/trans isomerase, which is an enzyme that
induces conformational change in other peptides; they speciﬁcally recog-
nize phosphorylated Pro-directed Ser/Thr (pSer/Thr-Pro) peptide se-
quences [9]. Up to the present, numerous PIN1 binding substrates have
been identiﬁed that undergo conformational changes. Based on these
ﬁndings, PIN1 has been proposed to be involved in many cellular func-
tions via protein modulation, including changing catalytic activity, modi-
fying phosphorylation status, adjusting protein stability, changing
cellular localization and others [10]. Additionally, PIN1 has been found
to be signiﬁcantly overexpressed in several human cancers, including
breast, lung, oral and prostate cancers. The expression level of PIN1 in
these cancers has been shown to be positively associatedwith a poor clin-
ical outcome [11–13]. Similar results have been reported in breast cancers
when cancer cell lines were comparedwith non-transformed or primary
mammary epithelial cells [13]. PIN1 also has been reported to inactivate
and destabilize a large number of growth inhibitors or tumor suppressors
[14]. In this context, it is known that KLF10 protein expression is lost
during breast and pancreatic cancer progression [7,15] and that the ex-
pression levels of PIN1 and KLF10 show a reverse relationship.
Given the reverse relationship between the expression levels of
KLF10 and PIN1 as described above, we hypothesized that PIN1 and
KLF10 may interact with each other and that this might explain the
inverse relationship during tumorigenesis. In this report, we have
explored the interaction between human KLF10 and PIN1 and identiﬁed
the kinase that phosphorylates a site on KLF10 enabling PIN1 to bind.
Interaction between PIN1 and KLF10 makes the latter unstable and
increases signiﬁcantly the degradation of KLF10. Our ﬁndings help us
to understand the roles of KLF10 and PIN1 in tumorigenesis and may
open a new avenue that allows the development of targeted therapeu-
tics for human diseases where there is aberrant KLF10 repression.2. Results
2.1. KLF10 is a PIN1 interacting protein in cells
To explore proteins thatmay regulateKLF10 activity, yeast two-hybrid
screening was performed using a HeLa-S3 cDNA library with pGBKT7-Fig. 1. Identiﬁcation of PIN1 as a KLF10-interacting protein. (A) The association between PIN1 a
with pRK5-Flag or pRK5-Flag-KLF10. Whole-cell extracts were incubated with equal amounts o
presence of KLF10 in the pulled-down proteins was examined by immunoblotting using anti-F
demonstrated by co-immunoprecipitation. H1299 cells were transfected with pCDNA3-HA-KLF
cipitation was performed using anti-Flag antibody. HA-KLF10 and Flag-PIN1 in the immunoprec
HA antibody (upper panel) or anti-PIN1 antibody (lower panel), respectively. (C) The interactio
itation.H1299 cell lysateswere immunoprecipitatedusing either anti-KLF10 or anti-PIN1 antibo
KLF10 or PIN1 antibodies. IP, immunoprecipitate.KLF10 (full length) as bait. Among the interacting clones, PIN1 was
isolated three times, which was a higher frequency than that of the
known KLF10-interacting proteins SIAH1/2 (data not shown). To
identify whether KLF10 and PIN1 interact in cells, whole cell extracts
from three different human cancer cells (non-small cell lung carcinoma
H1299, alveolar adenocarcinomaA549, or cervical carcinoma SiHa cells)
were transfected with a Flag-tagged full length KLF10 plasmid and
subjected to a GST pull-down assay (Fig. 1A). As shown in Fig. 1, the
overexpressed KLF10 was pulled down by GST-PIN1 but not by GST
alone, which indicates an association between KLF10 and PIN1. This
interaction was further conﬁrmed by co-immunoprecipitation of
H1299 cell extracts containing transfected full length human KLF10
and PIN1 (Fig. 1B). Using α-Flag antibodies, we were able to co-
immunoprecipitate Flag-PIN1 with HA-KLF10 (Fig. 1B right panel,
lane 4) while protein G beads alone was used as a control (Fig. 1B
right panel, lane 3). Moreover, to conﬁrm that the endogenous
KLF10 and PIN1proteins also associate, cell extracts were prepared
from H1299 cells and then immunoprecipitated with KLF10 or IgG
antibodies. As shown in Fig. 1C, PIN1 was co-precipitated with KLF10
but not with IgG antibody. Together, these results demonstrate that
KLF10 is a PIN1-interacting protein both in vitro and in vivo.2.2. KLF10 interacts with PIN1 in a phosphorylation-dependent manner
As PIN1 preferentially interacts with phosphoproteins [9], we
next checked whether KLF10 is phosphorylated in cells using an
in vivo phosphorylation assay. H1299 cells transiently transfected
with HA-KLF10 or HA alone were labeled with [32P] orthophosphate
and then treated with a phosphatase inhibitor cocktail containing
phosphatase 1, 2A, and 2B. Analysis of HA-immunoprecipitated KLF10
by autoradiography revealed that full-lengthHA-KLF10 underwent phos-
phorylation, but not IgG nor HA (Fig. 2A). This result explicitly provides
that exogenous KLF10 can be phosphorylated in cells. In addition, in
order to prove that KLF10 is phosphorylated in vivo, H1299 cell lysates
were directly incubated with calf intestinal alkaline phosphatase (CIAP),
which removes existing phosphate group modiﬁcations, and the protein
was then analyzed by 6% Tris–Glycin SDS-PAGE in order to ascertain
whether the electrophoretic motility of the protein was modiﬁed by
phosphorylation. As shown in lane 3 of Fig. 2B, the majority of endoge-
nous KLF10 is present as a slower moving band, which is presumably
the phosphorylated form.When incubatedwith CIAP, the amount of pro-
tein present in the slowermoving bandwas decreased and the amount ofnd KLF10was detected by GST pulled-down. SiHa, A549 and H1299 cells were transfected
f bacterially expressed GST or GST-PIN1 immobilized on glutathione-sepharose beads. The
lag antibody that recognizes Flag-KLF10. (B) The interaction between PIN1 and KLF10 was
10 or pRK5-Flag-PIN1. The cells were lysed after 24 h post transfection, and immunopre-
ipitates and in the cell extracts were detected byWestern blotting usingmonoclonal anti-
n between endogenous PIN1 and KLF10 proteinswas demonstrated by co-immunoprecip-
dywith protein G beads, and the precipitateswere subjected to immunoblot analysis using
Fig. 2. KLF10 is a phosphorylated protein. (A) HA-KLF10 is phosphorylated in vivo. H1299 cells were transiently transfected with or without HA-KLF10 and then were labeled with [32P]
orthophosphate. Cell lysates were immunoprecipitated and detected for KLF10 expression by anti-HA antibody. Proteins were separated using 7.5% SDS-PAGE and transferred onto PVDF
membrane. Autoradiography was carried out in order to visualize the phosphorylated KLF10 (lane 2–4). Afterward, the same cell lysates were blotted with anti-HA antibody (lane 1).
(B) KLF10 undergoes an electrophoretic mobility shift in C33A cells after phosphatase treatment. Cell extracts from C33A cells were treated with alkaline phosphatase (CIAP) and with
or without phosphatase inhibitors for 30 min. Then the cell lysates were separated using 6% SDS-PAGE and immunoblotted with KLF10 antibody.
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more, in addition of a phosphatase inhibitor (PPase) to the CIAP, it was
found that the change was reversed with faster moving band being pro-
portionally decreased (Fig. 2B, lane 2). These band shift electrophoresis
results conﬁrm that KLF10 is phosphorylated in vivo.
PIN1 is known to target Ser/Thr-Pro motifs and to bind to a pro-
tein only when the serine or threonine preceding the proline is phos-
phorylated [16]. Taking the above into account, we investigated theFig. 3. Ser/Thr-Pro site phosphorylation of KLF10 is required for PIN1 binding. (A) Flag-KLF10 co
or pRK5-Flag-KLF10. The cellswere lysed 48 h post transfection and the immunoprecipitationsw
phatase (CIAP) for 30 min. This was followed byWestern blot analysis using anti-MPM-2 or ant
contains a Ser/Thr-Pro phosphorylation motif. KLF10 immunoprecipitate was isolated from C3
using 6% SDS-PAGE. Protein bands were identiﬁed by Western blotting using anti-KLF10 or a
were transfected with shVec or sh-KLF10. The cells were lysed 24 h post transfection and imm
Cell lysates were analyzed using 10% SDS-PAGE and the presence of the various proteins ident
a control in the Western analysis. (D) A phosphorylated Ser/Thr-Pro motif in KLF10 is required
The cells were lysed 48 h post transfection, and then incubated with equal amounts of bacter
down proteins were treated with alkaline phosphatase (CIAP) for 30 min and analyzed by West
sponds to a representative experiment out of two that were performed.phosphorylation of KLF10 at the Ser/Thr-Pro sites using a monoclo-
nal antibody MPM2 that recognizes speciﬁcally the pSer/Thr-Pro
motifs [17]. As shown in Fig. 3A, immunoprecipitated Flag-tagged
KLF10 protein from H1299 cells transiently transfected with pRK5-ﬂag-
KLF10 is recognized by the MPM2 antibody. However, after treating the
same lysates with CIAP, the signal recognition by the antibody is notice-
ably decreased (Fig. 3A, lane 3). These ﬁndings clearly indicate that
KLF10 contains one or more pSer/Thr-Pro motifs. Subsequently, studiesntains a Ser/Thr-Pro phosphorylation motif. H1299 cells were transfected with pRK5-Flag
ere performedusing anti-Flag antibody; then the lysateswere treatedwith alkaline phos-
i-Flag antibody tomeasure the immunoprecipitated protein levels. (B) Endogenous KLF10
3A cell lysate using either normal mouse IgG or anti-KLF10 antibody and then separated
nti-MPM2 antibody. (C) MPM2 immunoprecipitate contains KLF10 protein. H1299 cells
unoprecipitation was performed using either normal mouse IgG or anti-MPM2 antibody.
iﬁed by Western blot analysis using anti-KLF10 antibody as a probe. Tubulin was used as
for the PIN1 interaction. H1299 cells were transfected with pRK5-Flag or pRK5-Flag-KLF10.
ially expressed GST or GST-PIN1 immobilized on glutathione-sepharose beads. All pulled-
ern blotting using either anti-MPM-2 or anti-Flag antibody as a probe. Result shown corre-
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were performed. Fig. 3B and C shows that immunoprecipitated endoge-
nous KLF10 protein is recognized by the MPM2 antibody speciﬁcally
(Fig. 3B, right panel), and endogenous protein immunoprecipitated
with theMPM2 antibody is also recognized by a speciﬁc antibody against
KLF10 (Fig. 3C); this conﬁrms that endogenous KLF10 contains at least
one pSer/Thr-Promotif. Finally, the required presence of phosphorylated
Ser/Thr-Pro was demonstrated. Speciﬁcally, GST-PIN1 fusion protein was
able to pull downoverexpressed Flag-taggedKLF10 protein (Fig. 3D) and,
as expected, this protein was also recognized by the MPM2 antibody
(Fig. 3D, lane 2). Importantly, when treated with CIAP, the ability of
PIN1 to pull down KLF10 was reduced and the signal obtained with
MPM2 was also lower (Fig. 3D, lane 3). These ﬁndings together conﬁrm
that phosphorylation of KLF10 at one or more Ser/Thr-Pro motifs is
required for interaction with PIN1.
2.3. The Ser/Thr-pro motif at Thr93 of KLF10 is responsible for association
with PIN1
Human KLF10 is a 480-amino acid protein that contains a highly
conserved C-terminal DNA-binding domain like other SP1-like/KLF
transcriptional factors. The N-terminal regions of the Sp1-like/KLF pro-
teins aremuchmore variable and are involved in protein–protein inter-
actions and the subsequent gene regulation [15]. In order to identify the
domain within KLF10 that is required for interaction with PIN1, GST
pull-down experiments were performed using N-terminal (a.a. 1–215)
and C-terminal (a.a. 215–480) KLF10 fragments generated in H1299
cells by transiently transfected with the respective Flag-tagged con-
structs. The results revealed that N-terminal fragments of KLF10 inter-
act with PIN1 but not C-terminal fragments (Fig. 4B). Since multiple
Ser/Thr-Pro motifs are present in the N-terminal fragment of KLF10,
further studies were conducted to identify which of these Ser/Thr-Pro
motifs are required for interaction with PIN1. Single alanine substitu-
tions mutants of all six Ser/Thr-Pro motifs in N-terminal KLF10 frag-
ment were generated based on the motif prediction results (Fig. 4A
and C). Immunoprecipitated Flag-tagged KLF10 wild-type protein and
each of the six proteins with single alanine substitution mutations of
their Ser/Thr-Pro motifs still could be recognized by MPM2 antibody
except for the Thr93 mutant (T93A) (Fig. 4C). All of the mutants were
also tested tomeasure their interactionwith GST or theGST-PIN1 fusion
protein in GST-pull down assays and the only amino acid substitution
that reproducibly completely eliminated the association between PIN1
and KLF10 is T93A (Fig. 4D). However, we did ﬁnd that the binding
abilities of the Thr66 and Thr81 mutants were also somewhat lower
in this pull down assay, which suggest that more than one site may be
involved, perhaps only to a limited extent, in the KLF10 and PIN1 inter-
action. Finally, studieswere conducted to test whether Thr93 is respon-
sible for KLF10 and PIN1 binding. The results are presented in Fig. 4E,
middle panel. HA-PIN1 was found to be co-immunoprecipitated with
Flag-KLF10 but was not co-immunoprecipitated with a mutant KLF10
(T93A) or when a mutant PIN1 was used (W34A, which stops Pin1
interacting with its substrate). Following the same procedure, but
using anti-HA antibodies, it was found that the Flag-KLF10 wild type
was co-immunoprecipitated with HA-PIN1, but not with the mutant
KLF10 (T93A), or with the mutant PIN1 (W34A) (Fig. 4E, right panel).
These ﬁndings conﬁrm that the Ser/Thr-Pro motif at Thr93 of KLF10
alone is essential for association with PIN1.
2.4. PIN1 association affects KLF10 stability
Given the speciﬁc interaction between PIN1 andKLF10, the next cru-
cial question is whether this interaction has any biological signiﬁcance.
The fact that Pin1 inactivates and destabilizes a large number of growth
inhibitors and tumor suppressors [14] suggests that Pin1might regulate
KLF10 protein stability. To explore this possibility, KLF10 immunoblot-
ting was performed and protein levels were compared between thePin1+/+ and Pin1−/−mouse embryonic ﬁbroblasts (MEFs). Increased
KLF10 expression was observed in the Pin1−/−MEFs compared to the
Pin1+/+ MEFs (Fig. 5A). In order to ensure that this decreased KLF10
level in the Pin1+/+ MEFs was due to the interaction of KLF10 with
Pin1, Pin1+/+ MEFs were transiently transfected with Flag-tagged
KLF10 wild type (WT) or the alanine (T93A) or aspartic acid (T93D,
mimic phosphorylation) substitution mutants of KLF10. The expression
level of KLF10 T93D was noticeably reduced in the cells when wild
types KLF10 and T93A KLF10 were expressed (Fig. 5B), which suggest
that phosphorylation of Thr93 of KLF10 affects protein stability. To further
conﬁrm that Pin1 silencing also increases KLF10 level, a shRNA targeting
Pin1 (Pin1-shRNA) was transfected into MEF and human cervical cancer
C33A cells, which was followed by monitoring of endogenous Klf10 pro-
tein expression. In contrast to the vector only (shVec) or control shRNA
(shLuc) transfected groups, cells transfected with the shPin1 obviously
exhibit a lower level of Pin1 expression and, at the same time, also
showed a higher level of KLF10 expression (Fig. 5C). This supports the
hypothesis that KLF10 is more stable in PIN1 deﬁcient cells.
To further support the notion that Pin1 is important for KLF10
turnover, a cycloheximide (CHX) chase experiment was performed
and the effects of Pin1 on KLF10 stability in the presence of exogenously
expressed PIN1WT or theW34Amutantwere observed. Pin1−/−MEFs
were transfected with a ﬁxed amount of plasmid expressing Flag-PIN1
WT or the W34A mutant that failed to bind to KLF10 (Fig. 4E). At 24 h
after transfection, cells were exposed to cycloheximide to inhibit de
novo KLF10 synthesis and the steady-state levels of endogenous KLF10
were determined using Western blotting at the indicated time points.
For the Pin1−/− MEFs transfected with Flag-Pin1 WT, the calculated
half-life of KLF10 is about 15 min (Fig. 6A and C). This half-life increased
signiﬁcantly to about 30 min when the cells were expressing the W34A
PIN1 mutant (Fig. 6B and C). These results support strongly the idea
that when PIN1 binds to KLF10 this leads to greater KLF10 instability.
We have demonstrated above that PIN1's association with KLF10
requires phosphorylation at Thr93 of KLF10. In these circumstances, it is
then logical to assume that T93A Klf10 mutants do not only loose PIN1
binding ability but also that they then become more stable than the
wild type KLF10. To prove this, the cycloheximide chase experiments
were repeated using the KLF10-T93A mutant and the results are shown
in Fig. 6D to F. The half-life in cells of KLF10-T93A was about 4 h, while
that of wild type HA-KLF10 was only about 1.5 h. These results show
that PIN1 and its phosphorylation-dependent association with KLF10
affect KLF10 stability and also conﬁrm the essential role of Thr93 phos-
phorylation in regulating the stability of KLF10.
In order to identify the expression pattern between KLF10 and PIN1
in cancer patients, 20 pancreatic cancer tissue samples were obtained
from surgical specimens of patients and studied using immunohisto-
chemistry. In the stage IIb cases of pancreatic cancer specimen, KLF10
was detected intensive staining (+++) at high levels about 90% in
the cytoplasm (Supplementary Fig. S1). On the other hand, KLF10 was
shown weak, almost undetectable staining (− or +), in all specimens
of magniﬁcent grade tissues. As predicted, the level of PIN1 protein
was shown in a reversed relationship opponent to KLF10 in these
tumor specimens: negative in the stage IIb (− or +) and dense (++
to +++) in the stages III and IV (Supplementary Fig. S1). These obser-
vations further conﬁrm the reversed expression pattern between KLF10
and PIN1 in cancer patients.
2.5. Thr93 phosphorylated KLF10 is a RAF-1 target
In order to predict which kinase phosphorylates Thr93 of KLF10, the
human protein reference database phosphoMotif Finder (http://www.
hprd.org/PhosphoMotif_ﬁnder) was used and the program predicted
four putative kinase groups as possibly being involved. Among these
four groups, RAF-1 was selected for further study because RAF-1 was
predicted as having only one recognition site, namely Thr93, on KLF10.
Protein–protein association between KLF10 and RAF-1 in cells was then
Fig. 4.Mapping the PIN1 interaction site in KLF10. (A) A schematic representation of KLF10 depicts all of the S/T-P (Ser/Thr-Pro) motifs present in the N-terminal region of KLF10. (B) The
N-terminal region but not the C-terminal region of KLF10 binds PIN1 in a GST pull down assay. H1299 cells were transfected with full length (1–480), N-terminal (1–215), or C-terminal
(215–480) of the pRK5-Flag-KLF10, and cell extractswere prepared24 h post transfection. EitherGST or GST-full length PIN1 fusion proteinwas thenpuriﬁed from E. coli BL-21 and used in
the pull down assay. The GST-PIN1 pulled down proteins were analyzed byWestern blotting using anti-ﬂag antibody as the probe. (C) Thr93 of KLF10 is required for KLF10 and PIN1 in-
teraction. Individualmutants, namely T66A, T81A, T93A, S97A, S140A, S206A orwild type (WT), of pRK5-Flag-KLF10were transiently expressed in H1299 cells. Approximately, 24 h after
transfection, the cells were harvested for immunoprecipitation using anti-Flag antibody. Mutant T93A showed the least binding ability to MPM2. (D) The phosphorylated Ser/Thr-Pro site
at Thr93 of KLF10 is responsible for PIN1 interaction; this was demonstrated by GST pull down assay. GST or GST-PIN1 pull-down assays were performed using lysates of H1299 cells ex-
pressing Flag-taggedWT, T66A, T81A, T93A, S97A, S140A, or S206AKLF10. GSTwasused as thenegative control for thepull downassay.Westernblot studies using anti-Flag antibodywere
performed to analyze the proteins pulled down by GST-PIN1. (E) Thr93 phosphorylation is required for KLF10–Pin1 interaction as demonstrated by co-immunoprecipitation. H1299 cells
were co-transfected with pCDNA3-HA-KLF10 (WT or T93A) and pRK5-Flag-PIN1 (WT or W34A). The cells were lysed 24 h post transfection, and immunoprecipitation was performed
using anti-HA or anti-Flag antibody. Western blot analyses of the immunoprecipitates and of the cell extract were done using monoclonal anti-HA antibody (up panel) or anti-PIN1 an-
tibody (lower panel) as probes.
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(data not shown). Subsequently, to test whether RAF-1 is able to phos-
phorylate KLF10, an in vitro kinase assay was performed using either
GST alone or the GST-KLF10 fusion protein as the substrate and active re-
combinant RAF-1 as the kinase; the reaction was carried out in the pres-
ence of radiolabeled [λ-33P] ATP as a phosphate donor. RAF-1 activity
targeting KLF10 should result in the incorporation of radiolabeled phos-
phate into the KLF10 protein. Incubation of recombinant GST-KLF10 pro-
tein with RAF-1 revealed the presence of a phosphorylated GST-KLF10
band at about 95 kDa (Fig. 7A, lane 4); this band was absent when
RAF-1 was not added (Fig. 7A, lane 3) and also was not present whenGST protein was incubated with RAF-1 (Fig. 7A, lanes 1 and 2). Previous
studies have shown that RAF-1 is an autophosphorylated protein [18], it
was therefore not unexpected that a band at about 70 kDa is detected
whenever RAF-1 was used (Fig. 7A, lanes 2 and 4). The above ﬁndings
show that KLF10 is a phosphorylation substrate for RAF-1 in vitro.
To identify whether RAF-1 has the ability to phosphorylate KLF10 at
Thr93, we repeated the in vitro kinase assays but in the absence of
radiolabeled [λ-33P] ATP. Rather the protein was detected by Western
blotting using the Thr93 phosphorylation speciﬁc antibody anti-MPM2.
As predicted, incubation of recombinant GST-KLF10 protein with RAF-1
gave rise to a Thr93 phosphorylated GST-KLF10 band at about 95 kDa
Fig. 5. Depletion of PIN1 affects KLF10 protein expression level. (A) The steady state level of KLF10 is higher inMEF-Pin1 null cells. WT or PIN1 null MEFs were harvested after 24 h incu-
bation. Their lysates were subjected to immunoblotting using antibodies against KLF10 or PIN1. Tubulin was used as an equal loading control. (B) Point mutation of Thr93 affects KLF10
stability in MEF cells. MEF cells were transiently transfected with or without pRK5-Flag-KLF10WT, T93A (un-phosphorylated status), or T93D (phosphorylated status) for 24 h and then
harvested for immunoblotting using KLF10 antibody as a probe, and using Tubulin as a control. (C) KLF10 levels are increased by suppressing PIN1 expression. Vector only, Luc control
shRNA, or PIN1 shRNAwas transiently transfected intoMEF and C33A cells for 48 h. Total proteins were isolated and the level of KLF10 or PIN1 protein wasmeasured byWestern blotting
using their respective antibodies. Tubulin was used as a control. The experiments were repeated and a representative example is shown.
Fig. 6. PIN1 facilitates KLF10 protein degradation. (A) Endogenous Klf10 degradation is faster in MEF Pin1 null cells with re-expressed PIN1 WT than cells expressing the WW domain
mutant (W34A) PIN1. Pin1 null cells were transfected with PIN1 or its mutant and this was followed by cycloheximide chase (CHX) at indicated time points in order to determine
KLF10 stability. (B) The protein levels of (A) were quantiﬁed and are presented using Tubulin as a loading control; the relative KLF10 levels at time 0 were set to 100%. (C) The KLF10
T93A mutant is more resistant to degradation than WT protein in H1299 cells. KLF10 WT or T93A mutant was transiently expressed for 24 h in H1299 cells, and then was treated with
100 μg/mL cycloheximide (CHX) for the indicated time. The cell lysates were harvested and immunoblotted using anti-KLF10. (D) The protein level of (C) was quantiﬁed using Tubulin
as the loading control and the relative KLF10 levels at time 0 were set at 100%.
3040 Y.-C. Hwang et al. / Biochimica et Biophysica Acta 1833 (2013) 3035–3045
3041Y.-C. Hwang et al. / Biochimica et Biophysica Acta 1833 (2013) 3035–3045(Fig. 7B, lane 3). No phosphorylated bandwas detectedwhen the recom-
binant GST-KLF10 proteinwas incubated in the absence of RAF-1 (Fig. 7B,
lane 4). The speciﬁcity of RAF-1 relative to phosphorylation KLF10 was
also tested by adding a RAF-1 inhibitor. This prevented the phosphoryla-
tion of Thr93 in GST-KLF10 as shown in lane 5 of Fig. 7B. Furthermore,
when comparedwith GST-KLF10-T93A, a mutant which lacks PIN1 bind-
ing ability, the GST-KLF10 wild type exhibited greater RAF1 activated
phosphorylation as shown in Fig. 7C (the relative quantities are 1 and
0.3when lanes 4 and 6 are compared). Taking the above results together,
they conﬁrmed that RAF-1 phosphorylates the Thr93 of KLF10 in vitro.
Since the phosphorylation of Thr93 enables KLF10 and PIN1 to bind,
it seems likely that RAF-1 will have an effect on KLF10 stability that is
similar to that of PIN1. This was tested by using a RAF-1 siRNA to
knock down endogenous RAF-1 protein expression in A549 cells,
which was followed by determining the steady state levels of KLF10.
In the RAF-1 suppressed cells, KLF10 protein expression levels were
almost doubled than that of the control cells (Fig. 8A) while the level
of PIN1 protein was maintained at the same level. At the same time,
treatment with siRAF dramatically reduced KLF10 phosphorylation on
Thr93 as is demonstrated in Fig. 8B, where equal amounts of total pro-
tein extract from the differently treated cells were subjected to immu-
noprecipitation using anti-MPM2 antibody. The immunoprecipitated–
phosphorylated proteins were then analyzed by Western blotting
using anti-KLF10 speciﬁc antibody. The results conﬁrm that endogenous
PIN-1 contributes to KLF10 stability because of the presence of RAF-1
kinase activity.
3. Discussion
KLF proteins are drawing out more and more attention because of
the fact that they show changed expression in different cancers and be-
cause they seem to be related to the growth andmetastasis of numerous
tumor types [2,3]. KLF10 belongs to the KLF family subgroup that is in-
duced by TGF-β, BMP-2, and EGF. The protein mimics the effect ofFig. 7. RAF1 phosphorylates the Thr93 site of KLF10 in vitro. (A) RAF1 phosphorylates KLF10 as
from E. coli BL-21 and then in vitro kinase assays were carried out in the presence of [γ-33P]AT
Autoradiography (top) and Coomassie Blue staining (bottom) of GST or GST-KLF10 are shown
assays were performed as described earlier using GST alone and GST-full length KLF10 fusion p
equal amounts of each sample are resolved on separate SDS-PAGE gels with one being transf
antibody (top) and the other one being stained with Coomassie blue (bottom). (C) RAF1 ph
alone, GST-full length KLF10WTor T93A fusion proteins following the same procedures as descr
gel as the loading control and with the relative WT levels set to 1.TGF-β and inhibits cell proliferation and/or induces apoptosis when
overexpressed in various tumor and non-tumor cell lines [6,15]. Re-
duced expression of KLF10 has been reported to be associated clinically
with the progression status and metastasis in breast and pancreatic
cancers [7,15,19]. These observations encouraged us to study the
proteins that interact with KLF10 as these may be implicated in the
mechanism(s) of KLF10 associated tumorigenesis. In this report, we
have demonstrated that KLF10 interacts with PIN1. PIN1 is known to in-
teract with and regulate the stability of its phospho-substrates by
targeting the speciﬁc pSer/Thr-Pro motif. These substrates comprise a
range of oncogenic regulators and transcription factors that are involved
in many different biological processes [14]. Our results have demon-
strated that phosphorylation of KLF10 at the Ser/Thr-Pro motif pro-
motes its interaction with PIN1 and that this leads to an increased
degradation of KLF10 protein. Mutagenesis of all six Ser-Pro and Thr-
Pro motifs within the N-terminal of KLF10 conﬁrmed that the Thr93
motif plays a major role in the interaction between KLF10 and PIN1.
Overexpression of KLF10 has been shown tomimic the effect of TGF-
β in several cell types [20–22]. Recent studies have revealed that Pin1
also regulates Smad2/3 in response to TGF-β. Pin1 was found to reduce
Smad2/3 protein levels also via an interaction with the pSer/Thr-Pro
motifs in Smad2/3; in addition, it was also found that knocking down
Pin1 raises the protein levels of endogenous Smad2/3 [23,24]. It was
suggested that TGF-β might regulate KLF10 through Smad2/3, which
was investigated using transient transfection with KLF10 and a Smad
binding element reporter [21]. However, since that early report there
have been no further studies showing that Smad2/3 has the ability to di-
rectly regulate the protein level of KLF10. Moreover, Smad2 has also
been reported to be one of the targets of KLF10 [25], and overexpression
of KLF10 has been shown to enhance the TGF-β induced Smad2 phos-
phorylation [21]. Additionally, it has been shown that protein level of
KLF10 in human osteoblasts is increased within 30 min of TGF-β treat-
ment and shows an about 10-fold increase after 2 h when compared to
control levels [26]. The remarkably sharp kinetic changes in KLF10shown by in vitro kinase assay. GST or GST-full length KLF10 fusion proteins were puriﬁed
P, and in the absence (−) or presence (+) of RAF1. Samples were resolved by SDS-PAGE.
. (B) The phosphorylation site of RAF1 in KLF10 is the MPM2-epitope. The in vitro kinase
roteins. RAF1 and 0.3 μM RAF1 inhibitor (RAF1i) GW5074 were added as indicated. Two
erred to a polyvinylidene diﬂuoride membrane before immunoblotting with anti-MPM2
osphorylates Thr93 site of KLF10. Various in vitro kinase assays were carried using GST
ibed earlier (B). Quantiﬁcation of theMPM2 levelswas carried using theCoomassie stained
Fig. 8. RAF1 phosphorylates the Thr93 site of KLF10 in vivo. (A) A549 cells were treated with RAF1 siRNA (siRAF) or negative control siRNA (siNS) for 24 h before protein extraction. The
efﬁcient silencing of RAF1 by siRNA and the level of expression of KLF10 or PIN1 were assessed by immunoblot analysis using Tubulin as the loading control. (B) Equal amounts of total
protein extract were also subjected to immunoprecipitation using either anti-MPM2 antibody or normal mouse IgG, which was followed by Western blot analysis using anti-KLF10
antibody.
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cation that makes it more stable. In this report, we have shown that
KLF10 contains a distinctive PIN1 recognized pSer/Thr-Pro motif and
that this motif interacts with PIN1 directly. Using studies of the half-
life of KLF10, we showed that PIN1 regulates KLF10 protein degradation.
From these observations, even if the relationship between Smad2/3 and
KLF10 remains unsettled, it is reasonable to suggest that PIN1 switches
off the TGF-β pathway not only by reducing the half-life of Smad2/3, but
also by reducing the half-life of KLF10. This PIN1 regulatory mechanism
may be involved inmodulating the alternative effects of TGF-βwhereby
it can not only act as a suppressor of tumor progression in some cancers,
but also act as a promoter of tumor progression in other cancers.
In addition to cell growth, KLF family members are also involved
in the regulation of apoptosis during cancer progression [2]. Thus,
it is not surprising that there is increasing evidence indicating that
overexpression of KLF10 is able to induce apoptosis in multiple cell
types [22,27–31]. Klf10 has been reported to be involved in the transcrip-
tional regulation of members of the Bcl-2 family. Overexpression of Klf10
in oligodendroglial precursor and human K562 leukemia cells has been
shown to result in decreased levels of the anti-apoptotic proteINS Bcl-2
and Bcl-XL and increased levels of the pro-apoptotic members of the
Bcl-2 family, such as Bim and Bax; the result of these changes in expres-
sion is an induction of apoptosis [27,32]. Coincidentally, there is also
growing evidence to suggest that Pin1 is important to apoptosis of
tumor cells [33]. Pin1 also interacts with the Bcl-2 family, including bind-
ing to the phosphorylated anti-apoptotic factor Bcl-2 and to the phos-
phorylated pro-apoptotic factor BAX in order to inhibit apoptosis in
cancer cells [34,35]. PIN1 is highly abundant in various cancers and
plays an important role in a range of oncogenic signaling pathways. Inhi-
bition of PIN1 results in apoptosis or a suppression of oncogenesis [36]. As
we have found that PIN1 suppresses KLF10 protein levels, this suggests a
mechanismwhereby the interaction between PIN1 andKLF10 is also able
to trigger apoptosis during oncogenesis.
Phosphorylation appears to be a common modiﬁcation among
transcription factors and seems to be a mechanism that regulates
the ‘on–off’ switch of a surfeit of biological processes. The KLF family
is no exception and phosphorylation of these proteins seems to regulate
their activities including increasing the transcription of target genes,
increasing or disrupting their binding ability to various effector proteins
and changing the cellular localization of various proteins [37]. In this
report, we have demonstrated that RAF1 is one of the kinases that
regulate the phosphorylation of the Thr93 of KLF10. Suppression of
RAF1 expression apparently decreases level of phosphorylated target
KLF10 motif, which then reduces PIN1 binding to KLF10, and this inturn increases the protein level of KLF10 by increasing protein stability.
RAF1, also called C-RAF, is amember of the RAF kinase family; this family
is involved in the RAS–RAF–MEK–ERK signal transduction cascade [38].
In addition toMEK signaling, RAF1 alsomediates numerous other biolog-
ical effects. For example, RAF1 has been reported to activate Cdc25A and
to inactive retinoblastoma protein via phosphorylation, which then regu-
lates the cell cycle [39]. It also directly binds to various apoptotic proteins,
including Bcl-1, BAD, VDACs, ASK1, andMST2, bywhich it is able to inhib-
it apoptosis [40]. In addition, RAF1 has been reported to suppress Rok-α
activity, which then prevents cell motility and differentiation [41,42].
Dougherty et al. presented that phosphorylation is required for RAF1 ac-
tivation. The hyperphosphorylated RAF1 (S29, S43, S289, S296, S301, and
S642) is subsequently dephosphorylated and returned to a signaling-
competent state through interactions with the protein phosphatase
PP2A and Pin1 [43], both of which are required for the recycling of
RAF1. They further suggested that RAF1 interacts with PIN1 but only
when the feedback sites are phosphorylated (ﬁve of which are pSP
sites). Comparatively, the inhibition of PIN1 activity has also been
shown to trigger the apoptosis of tumor cells [44]. Thus, in addition to
the core components of the RAF pathway, PIN1 may be an appealing
switch in tumors with constitutive Raf-dependent signaling. Also inter-
estingly,more andmore ﬁndings are supporting the idea that KLF protein
associated cancer is accompanied with activated Ras signaling [3]. Based
on our ﬁndings, this is the ﬁrst time that RAF1 has been shown to be able
to phosphorylate KLF10 at Thr93 site in order to generate PIN1-binding
site that allows the consequential degradation of KLF10. These observa-
tions suggest that RAF1 may promote tumorigenesis in concert with
KLF10. However, the detail mechanisms still need to be further
investigated.
In summary, the current study indicates that human KLF10 is one of
the substrates of RAF1 kinase. The phosphorylation of the Thr93 site of
KLF10 by RAF1 generates a PIN1-binding site within KLF10. Further-
more, this phosphorylation of the Thr93 site in KLF10 then enhances
the binding of PIN1 to KLF10, which, in turn, increases the rate at
which KLF10 degrades.
4. Materials and methods
4.1. Cell culture
Human lung carcinoma cell lines A549/H1299 and pancreatic cancer
cell line PANC-1 cells were purchased from ATCC (Manassas, VA, USA);
the three cell lines were cultured in RPMI 1640 medium (Invitrogen)
supplemented with 10% fetal bovine serum (FBS) (Biological Industries),
Table 1
shRNA insert sequence and sequences of the siRNA fragment.
Name Sequence
pLKO.1-shPIN1-1 5′-GCCATTTGAAGACGCCTCGTT-3′
pLKO.1-shPIN1-2 5′-AGAAGCCATTTGAAGACGCCT-3′
pLKO.1-shPIN1-3 5′-AGGAGAAGATCACCCGGACCA-3′
pLKO.1-shPIN1-4 5′-CCACCGTCACACAGTATTTAT-3′
pLKO.1-shPIN1-5 5′-CCAGAAGATCAAGTCGGGAGA-3′
pLKO.1-shPin1-1 5′-GCCATGTGATTTGGTATCTAT-3′
pLKO.1-shPin1-2 5′-GAGGTCAGATGCAGAAACCAT-3′
pLKO.1-shPin1-3 5′-CCATTTGAGGATGCGTCGTTT-3′
pLKO.1-shPin1-4 5′-GCTGGGAGAAGCGTATGAGTC-3′
pLKO.1-shPin1-5 5′-CAATGGCTATATCCAGAAGAT-3′
pLKO.1-shKLF10 5′-GAACCCTCTCAAGTGTCAAAT-3′
pLKO.1-shLuc 5′-CAAAUCACAGAAUCGUCGUAU-3′
siRAF1 5′-GACGUUCCUGAAGCUUGCCUUCUGU-3′
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cervical carcinoma cell lines SiHa and C33A were also purchased from
ATCC. The Pin1 knockdown and WT mouse embryonic ﬁbroblast (MEF)
cells were gifts from P.J. Lu (National Cheng-Kung University, Taiwan).
These cells were grown in Dulbecco's modiﬁed of Eagle's medium
(DMEM) supplemented with 10% FBS and 2 mM L-glutamine at 37 °C
in 5% CO2. For transient transfection, exponentially growing cells were
transfected with plasmid DNA using Lipofectamine 2000 reagent
(Invitrogen) as the transfection agent according to the manufacturer's
instruction. Cells were harvested at 24–48 h post-transfection.
4.2. Plasmid constructs and site-directed mutagenesis
The expression plasmids Flag-KLF10 and HA-KLF10 (wt or mt) have
been described previously [28]. To construct the PIN1 expression
vectors, the DNA fragmentswere ampliﬁed by polymerase chain reaction
(PCR) from pEGFP-PIN1 (wild-type and W34A substitution mutants),
which were gifts from P.J. Lu, and subcloned either into the EcoRI and
SalI sites of pRK5 (Flag-PIN1), or with a HA-tag into the EcoRI and XhoI
sites of pcDNA3 (Invitrogen).
The bacterial expression plasmid encoding glutathione S-transferase
(GST), pGEX-5 was obtained from Amersham Biosciences. Bacterial ex-
pression plasmid encoding the GST-tagged PIN1 (wt) was constructed
from pEGFP-PIN1 by PCR ampliﬁcation using primers that introduced
a 5′ EcoRI site and a 3′ XhoI site, which was followed by ligation of the
amplicon into EcoRI and XhoI digested pGEX-5x-1 vectors. All inserts
were conﬁrmed by restriction digestion or sequencing.
Plasmids encoding amino acid substitution mutants of KLF10 were
generated by PCR-mediated site-directed mutagenesis. The codon
changes of Ser/Thr to Ala in the mutants were: T66A, T81A, T93A,
S97A, S140A and S206A. For the six amino acid substitutionmutant con-
structs, the residues were mutated to Ala in the pRK5-Flag-KLF10 back-
ground. All codon changes and DNA fragment exchanges were
conﬁrmed by sequencing.
4.3. Cellular extracts and protein stability measurements
Total cellular lysates were prepared in lysis buffer (20 mMTris–HCl,
pH 8.0; 150 mmNaCl; 1 mMEDTA; 1%NP-40) with 1:50 diluted prote-
ase inhibitor cocktail (Roche) and 1:10 diluted Phospho-Stop phospha-
tase inhibitor cocktail (Roche). The lysates were shaken for 10 min at
4 °C and clariﬁed by centrifugation at 14,000 ×g at 4 °C for 10 min. Pro-
tein concentration was determined by the bicinchoninic acid assay
(BCA) (Thermo Fisher Scientiﬁc).
For the protein stability assays, exponentially growing PIN1null MEF
cells were transfected using Lipofectamine 2000 (Invitrogen) with plas-
mid pRK5-Flag-PIN1 DNA expressing wild-type or W34A and the
H1299 cells were transfected with plasmid HA-KLF10 DNA expressing
wild-type or T93A. Cells were treated with 100 μg/mL cycloheximide
(Sigma) at 24 h post-transfection and harvested at 0 (untreated) or indi-
cated time points after cycloheximide treatment. Cell extracts were pre-
pared as described above, which was followed by immunoblotting.
4.4. GST fusion protein puriﬁcation and GST-Pin1 in vitro protein–protein
interaction studies
GST fusion proteins were puriﬁed as described previously [28] with
modiﬁcations as indicated below. Protein expression was induced in
BL21 Escherichia coli by incubation with 2 mM IPTG (Promega) for
16 h at 30 °C. The cells were pelleted, resuspended in buffer A
(20 mM HEPES, pH 8.0; 1 M NaCl; 0.2 mM EDTA, pH 8.0; 0.5 mM DTT
and 0.5 mMPMSF), and sonicated. Following clariﬁcation by centrifuga-
tion, the supernatant was incubated with glutathione-sepharose 4B
resin (GE Healthcare) and shaken at 4 °C for 16 h. The resin was then
washed four times with buffer BD (0.1 M KCl; 20 mM HEPES, pH 8.0;
0.2 mM EDTA, pH 8.0; 20% glycerol; 0.5 mM PMSF and 0.5 mM DTT).Bound proteins were eluted by boiling in sample buffer containing
SDS, and detected by immunoblotting.
To detect the interaction between KLF10 and PIN1, cells were lysed
as described above. Equal amounts of GST or GST-PIN1 were incubated
with 300 μg of total cell lysate from cells transiently transfected with
Flag-KLF10 for 4 h at 4 °C. The beads were washed ﬁve times with
lysis buffer; bound proteins were eluted by boiling in 2× SDS-PAGE
loading buffer (125 mM Tris–HCl, pH 6.8, 4% SDS, 20% glycerol, 0.01%
bromphenol blue, and 200 mMDTT). The eluted proteinswere resolved
by SDS-PAGE and detected by immunoblotting using Flag antibody
(Sigma-Aldrich). To demonstrate the need for KLF10 phosphorylation
to allow interactionwithGST-PIN1, the extractswere dephosphorylated
by incubating with 50 units of calf intestinal alkaline phosphatase
(CIAP) (Sigma-Aldrich) for 30 min at 37 °C prior to incubation with
the GST-containing resins.
4.5. shRNA and siRNA
PIN1 and KLF10 suppression shRNA plasmids pLKO.1-shPIN1,
pLKO.1-shPin1, pLKO.1-shKLF10, and pLKO.1-shLuc were purchased
from the National RNAi Core Facility (Academia Sinica, Taiwan). A
clone expressing luciferase shRNA (pLKO.1-shLuc) was the non-
targeting shRNA control. The insert sequences are listed in Table 1.
Cell transfection was performed on the cells as described previously.
The siRNAs used in the experiments were purchased from Invitrogen:
Stealth RNAi Negative Control Med GC (12935-300), Stealth RNAi for
RAF1, and their sequences are also listed in Table 1. For siRNA transfec-
tion, the cells were transfected with 200 nmol/L RAF1-siRNA or control
siRNA using Lipofectamine 2000 reagent (Invitrogen) as a transfection
agent according to the manufacturer's instruction. After 24–48 h of
transfection, protein expression was assessed by Western blotting.
4.6. Immunoprecipitation and immunoblotting
For immunoprecipitation, cells were lysed as above and then incu-
bated with anti-Flag (Sigma-Aldrich), anti-HA (Roche) or anti-MPM2
(Millipore) antibodies overnight at 4 °C with continuous shaking. Im-
mune complexes were recovered using fast-ﬂow protein G Sepharose
beads (Millipore). The beads were then washed four times with lysis
buffer and complexes eluted using 2× SDS-PAGE loading buffer.
Immunoprecipitated proteins or cell lysates were immunoblotted
with anti-HA antibody (1:2000 dilution, Roche), anti-Flag antibody
(1:2000 dilution, Sigma-Aldrich), anti-PIN1 antibody (1:2000 dilution,
Santa Cruz Biotechnology), anti-MPM2 antibody (1:2000 dilution,
Millipore), anti-KLF10 mono-clone antibody [1:2000 dilution, [29]],
anti-RAF1 antibody (1:2000 dilution, Cell Signaling Technology) or
anti-Tubulin antibody (1:5000 dilution). Bound antibody was visual-
ized using SuperSignal West Pico Chemiluminescent Substrate (Pierce
Chemical) after incubation of the blot with peroxidase-conjugated sec-
ondary antibody for 1 h.
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H1299 cells transfected with empty pcDNA3-HA vector or
pcDNA3-HA vector encoding HA-tagged KLF10 were labeled for 3 h
with 0.3 μCi/mL [32P] orthophosphate in phosphate-free medium in
the presence of RPMI. Cells were then harvested and the HA-tagged
KLF10 was immunoprecipitated, as described previously.
The in vitro phosphorylation assays of the KLF10 wild type and its
Thr93 mutant by RAF1 were carried out in a total volume of 60 μL
that contained equal amounts of GST or GST-KLF10 (wt or T93A), ki-
nase buffer (Cell Signaling Technology), protease inhibitor cocktail
(Roche), Phospho-Stop phosphatase inhibitor cocktail (Roche) and
50 ng recombinant active kinase (Millipore). To demonstrate that
RAF1 was required for the phosphorylation of KLF10, some reaction
samples had 0.25 μM RAF1 inhibitor GW-5074 (Sigma-Aldrich)
added. The enzyme reactions were initiated by the addition of
20 μM unlabeled ATP and 2 μCi [γ-33P] ATP (Amersham). After incu-
bation at 30 °C for 30 min, the reactions were terminated by adding
2× SDS-PAGE loading buffer and subsequently boiled for 5 min. Each
sample was separated into two equal amounts and analyzed by SDS-
PAGE, one sample then underwent autoradiography or immunoblot-
ting with anti-MPM2 antibody as appropriate, while the other one
was stained with Coomassie Blue.
Abbreviations
BMP bone morphogenetic protein
CIAP calf intestinal alkaline phosphatase
GST glutathione-S-transferase
KLF10 Krüppel-like factor 10
MEFs mouse embryonic ﬁbroblasts
PIN1 peptidyl-prolyl cis–trans isomerase NIMA-interacting 1
PPase phosphatase
pSer/Thr-Pro phosphorylated Pro-directed Ser/Thr
TIEG1 TGF-β inducible early gene-1
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